{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:18:20Z","timestamp":1790435900277,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.anndiagpath.2020.151582","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T12:22:06Z","timestamp":1597234926000},"page":"151582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression"],"prefix":"10.1016","volume":"48","author":[{"given":"Neshat","family":"Nilforoushan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda A.","family":"Moatamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.anndiagpath.2020.151582_bb0005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2014.06.002","article-title":"A nationwide study of serous \u201cborderline\u201d ovarian tumors in Denmark 1978\u20132002: centralized pathology review and overall survival compared with the general population","volume":"134","author":"Hannibal","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.anndiagpath.2020.151582_bb0010","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.pas.0000164030.82810.db","article-title":"Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up","volume":"29","author":"Longacre","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.anndiagpath.2020.151582_bb0015","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00428-016-2040-8","article-title":"Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria","volume":"470","author":"Hauptmann","year":"2017","journal-title":"Virchows Arch"},{"issue":"6","key":"10.1016\/j.anndiagpath.2020.151582_bb0020","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11912-008-0078-8","article-title":"Low-grade serous ovarian cancer: a unique disease","volume":"10","author":"Schmeler","year":"2008","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"10.1016\/j.anndiagpath.2020.151582_bb0025","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/PGP.0b013e31827630eb","article-title":"Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry","volume":"32","author":"Ali","year":"2013","journal-title":"Int J Gynecol Pathol"},{"issue":"3","key":"10.1016\/j.anndiagpath.2020.151582_bb0030","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/path.3967","article-title":"Low-grade serous carcinomas of the ovary contain very few point mutations","volume":"226","author":"Jones","year":"2012","journal-title":"J Pathol"},{"issue":"35","key":"10.1016\/j.anndiagpath.2020.151582_bb0035","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.5438","article-title":"Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes","volume":"6","author":"Hunter","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.anndiagpath.2020.151582_bb0040","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF03401664","article-title":"The CDKN2A (p16) gene and human cancer","volume":"3","author":"Foulkes","year":"1997","journal-title":"Mol Med"},{"issue":"3","key":"10.1016\/j.anndiagpath.2020.151582_bb0045","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.celrep.2016.03.043","article-title":"MTAP deletions in cancer create vulnerability to targeting of the MAT2A\/PRMT5\/RIOK1 axis","volume":"15","author":"Marjon","year":"2016","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.anndiagpath.2020.151582_bb0050","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1534\/g3.114.014555","article-title":"Expression of MTAP inhibits tumor-related phenotypes in HT1080 cells via a mechanism unrelated to its enzymatic function","volume":"5","author":"Tang","year":"2015","journal-title":"G3"},{"key":"10.1016\/j.anndiagpath.2020.151582_bb0055","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2016.12.017","article-title":"Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: comparison with 9p21 FISH and BAP1 immunohistochemistry","volume":"104","author":"Hida","year":"2017","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.anndiagpath.2020.151582_bb0060","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/cncy.21928","article-title":"A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma: MTAP and BAP1 for mesothelioma diagnosis","volume":"126","author":"Kinoshita","year":"2018","journal-title":"Cancer Cytopathol"},{"issue":"4","key":"10.1016\/j.anndiagpath.2020.151582_bb0065","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/modpathol.2009.186","article-title":"CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival","volume":"23","author":"Krasinskas","year":"2010","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.anndiagpath.2020.151582_bb0070","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41379-019-0310-0","article-title":"MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma","volume":"33","author":"Chapel","year":"2020","journal-title":"Mod Pathol"},{"issue":"12","key":"10.1016\/j.anndiagpath.2020.151582_bb0075","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.5858\/arpa.2018-0273-OA","article-title":"Utility of methylthioadenosine phosphorylase compared with BAP1 immunohistochemistry, and CDKN2A and NF2 fluorescence in situ hybridization in separating reactive mesothelial proliferations from epithelioid malignant mesotheliomas","volume":"142","author":"Berg","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"11","key":"10.1016\/j.anndiagpath.2020.151582_bb0080","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/00000478-199611000-00003","article-title":"Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors","volume":"20","author":"Burks","year":"1996","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.anndiagpath.2020.151582_bb0085","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/00000478-199611000-00004","article-title":"Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases","volume":"20","author":"Seidman","year":"1996","journal-title":"Am J Surg Pathol"},{"issue":"19","key":"10.1016\/j.anndiagpath.2020.151582_bb0090","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.1158\/0008-5472.CAN-04-2067","article-title":"Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors","volume":"64","author":"Ho","year":"2004","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.anndiagpath.2020.151582_bb0095","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/path.4252","article-title":"KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma","volume":"231","author":"Tsang","year":"2013","journal-title":"J Pathol"},{"issue":"64","key":"10.1016\/j.anndiagpath.2020.151582_bb0100","doi-asserted-by":"crossref","first-page":"6870","DOI":"10.18632\/oncotarget.27326","article-title":"BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma","volume":"10","author":"Chui","year":"2019","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.anndiagpath.2020.151582_bb0105","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0165-4608(95)00157-3","article-title":"Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-\u03b11, interferon-\u03b21, and other 9p21 markers in human malignant cell lines","volume":"86","author":"Zhang","year":"1996","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.anndiagpath.2020.151582_bb0110","series-title":"Progress in polyamine research: novel biochemical, pharmacological, and clinical aspects. Advances in experimental medicine and biology","first-page":"165","article-title":"Human 5\u2032-deoxy-5\u2032-methylthioadenosine phosphorylase: kinetic studies and catalytic mechanism","author":"Zappia","year":"1988"},{"issue":"2","key":"10.1016\/j.anndiagpath.2020.151582_bb0115","first-page":"1122","article-title":"MTAP deficiency is associated with an unfavourable prognosis and platinum resistance in ovarian cancer","volume":"10","author":"Ding","year":"2017","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.anndiagpath.2020.151582_bb0120","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5858\/arpa.2014-0057-RA","article-title":"The utility of immunohistochemistry in the differential diagnosis of gynecologic disorders","volume":"139","author":"Kaspar","year":"2015","journal-title":"Arch Pathol Lab Med"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913420301258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913420301258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:33:02Z","timestamp":1761078782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913420301258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":24,"alternative-id":["S1092913420301258"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2020.151582","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2020.151582","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151582"}}